Table 1 Characteristics of the patients
From: Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China
Total (n = 11,252) | ICU (n = 7009) | General ward (n = 4243) | |
|---|---|---|---|
Age, years, median (range) | 59.31 (46 days-105 years) | 61.92 (46 days-104 years) | 52.67 (11 months-105 years) |
Age, year, mean ± SD | 55.74 ± 16.20 | 58.37 ± 14.85 | 51.40 ± 17.35 |
Sex, n (%) | |||
Male | 7323 (65.08) | 4648 (66.31) | 2675 (63.05) |
Female | 3929 (34.92) | 2361 (33.69) | 1568 (36.98) |
Pregnancy, n (%) | 48 (0.43) | 12 (0.17) | 36 (0.85) |
Allergy history, n (%) | 814 (7.23) | 550 (7.85) | 264 (6.22) |
Hypertension, n (%) | 2106 (18.72) | 1562 (22.29) | 544 (12.82) |
Unstable angina, n (%) | 1461 (12.98) | 1443 (20.59) | 18 (0.42) |
Acute pancreatitis, n (%) | 640 (5.69) | 139 (1.98) | 501 (11.81) |
Consistency with the indications*, n (%) | 1567 (13.93) | 648 (9.25) | 919 (21.66) |
Mixed with other drugs | 1739 (15.46) | 1715 (24.47) | 24 (0.57) |
Combined with other drugs, n (%) | 272 (3.88) | 301 (7.09) | 573 (5.09) |